The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
Authors
Keywords
Non-small cell lung cancer, Deletion mutation, Brain metastasis, Point mutation, Lung and intrathoracic tumors, Cancer detection and diagnosis, Prognosis, Metastasis
Journal
PLoS One
Volume 13, Issue 2, Pages e0192161
Publisher
Public Library of Science (PLoS)
Online
2018-02-16
DOI
10.1371/journal.pone.0192161
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
- (2018) Min Young Baek et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
- (2017) E-E Ke et al. Journal of Thoracic Oncology
- Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations
- (2017) Zhen Zheng et al. Journal of Cancer
- Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis
- (2016) Qingyuan Huang et al. CHEST
- Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer
- (2016) Bradley J. Stish et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- EGFR mutation status on brain metastases from non-small cell lung cancer
- (2016) Fred Hsu et al. LUNG CANCER
- Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Shigehiro Yagishita et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma
- (2015) Bo Li et al. JOURNAL OF NEURO-ONCOLOGY
- EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma
- (2015) Kosuke Tanaka et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan
- (2015) Jian Guan et al. MEDICAL ONCOLOGY
- STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation
- (2015) Mohini Singh et al. Oncotarget
- Noninvasive Saliva-basedEGFRGene Mutation Detection in Patients with Lung Cancer
- (2014) Fang Wei et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection
- (2014) Jae Hyun Jeon et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Risk Factors for Brain Metastases in Locally Advanced Non-Small Cell Lung Cancer With Definitive Chest Radiation
- (2014) Zhe Ji et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases
- (2014) Yi-Lin Chen et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2014) Yaxiong Zhang et al. PLoS One
- Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
- (2014) Karmen Stanic et al. Radiology and Oncology
- The Management of Brain Metastases in Non-Small Cell Lung Cancer
- (2014) Scott Owen et al. Frontiers in Oncology
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Treatment of Stage IV Non-small Cell Lung Cancer
- (2013) Mark A. Socinski et al. CHEST
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
- (2013) James W. Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
- (2013) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial
- (2013) Xiao-xiao Dinglin et al. JOURNAL OF NEURO-ONCOLOGY
- Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis
- (2013) Yan Chen et al. LUNG CANCER
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy
- (2012) Hiroaki Akamatsu et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis
- (2012) Fang Nie et al. CANCER
- Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer
- (2012) Edward A. Monaco et al. CANCER
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features
- (2012) Akimasa Sekine et al. LUNG CANCER
- Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
- (2011) F. Barlesi et al. ANNALS OF ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Factors associated with the development of brain metastases
- (2010) Jessica L. Hubbs et al. CANCER
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
- (2010) A. F. Eichler et al. NEURO-ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
- (2009) Jeong-Eun Kim et al. LUNG CANCER
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cigarette Smoking and Risk of Lung Metastasis from Esophageal Cancer
- (2008) J. A. Abrams et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
- (2008) Jian-quan Zhu et al. CANCER LETTERS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started